News Releases
- July 20, 2021Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study
- July 2, 2021Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials
- July 1, 2021Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO
- June 24, 2021Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards
- June 8, 2021Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study
- June 3, 2021Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
- June 1, 2021Annovis Bio’s ANVS401 Improves Speed and Accuracy in Alzheimer’s and in Parkinson’s Patients
- May 28, 2021Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
- May 27, 2021Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
- May 23, 2021Annovis Bio, Inc. Announces Pricing of Public Offering
- May 4, 2022Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
- April 28, 2022Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
- April 11, 2022Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Presentation - April 2023
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top